Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

The Business Research Company Updated 2025 Market Reports have released and offer essential trends and forecasts up to 2034. Early purchase is your competitive edge! LONDON, GREATER LONDON, UNITED KIN ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Combination therapies, such as Regeneron’s Libtayo (cemiplimab) and Merck’s Keytruda (pembrolizumab), are creating new treatment possibilities for advanced skin cancers, including basal cell carcinoma ...

Regeneron Canada, a biotechnology company focused on developing treatments for serious diseases, has reached a pricing and funding agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...